SG Americas Securities’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-25,000
Closed -$241K 3298
2021
Q4
$241K Buy
+25,000
New +$4.3M ﹤0.01% 2570

Other funds holding NVAX

SG Americas Securities's NVAX Position: Q1 2026 in Review

SG Americas Securities reduced its Novavax (NVAX) stake by 86% in Q1 2026, selling an estimated $7.57M and leaving 141,085 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1676.

SG Americas Securities first reported a position in NVAX in Q2 2013 and has held it in 49 quarters since. The position peaked at $14.6M in Q3 2024. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • SG Americas Securities held 141,085 shares of Novavax worth $1.15M as of Q1 2026.
  • SG Americas Securities sold 835,303 Novavax shares in Q1 2026, an estimated $7.57M.
  • Novavax made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1676 holding.
  • SG Americas Securities first reported a position in Novavax in Q2 2013 and has held it in 49 quarters since.
  • SG Americas Securities's Novavax position peaked at $14.6M in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.